Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Merck Sharp & Dohme LLC
Javier Cortes; David W Cescon; Hope S Rugo; Zbigniew Nowecki; Seock-Ah Im; Mastura Md Yusof; Carlos Gallardo; Oleg Lipatov; Carlos H Barrios; Esther Holgado; Hiroji Iwata; Norikazu Masuda; Marco Torregroza Otero; Erhan Gokmen; Sherene Loi; Zifang Guo; Jing Zhao; Gursel Aktan; Vassiliki Karantza; Peter Schmid; KEYNOTE-355 Investigators